[169Yb-dichlorodimethionine platinum (II) as a tumor-seeking radiopharmaceutical].
Biodistribution studies of 169Yb-dichlorodimethioninoplatin (II) in mice, bearing Ehrlich or leukemia tumors, showed increased uptake of the complex in the tumors. A large difference in the retention of the total injected activity was found depending on the optical isomeric form of the methionine part of the complex.